Previous research has shown that inhibiting key mitochondrial proteins in venetoclax-resistant AML has relieved some of the acquired resistance, suggesting that targeting additional mitochondrial proteins, including ETFA and ETFB, may be useful as a therapeutic strategy [45]. This evidence concerns the gene ETFB and acute myeloid leukemia.